PharmacyCodes



Toremifenum [Latin] en es it fr

Toremifenum [Latin] Brand names, Toremifenum [Latin] Analogs

Toremifenum [Latin] Brand Names Mixture

  • No information avaliable

Toremifenum [Latin] Chemical_Formula

C26H28ClNO

Toremifenum [Latin] RX_link

http://www.rxlist.com/cgi/generic2/toremifene.htm

Toremifenum [Latin] fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=151

Toremifenum [Latin] msds (material safety sheet)

Toremifenum [Latin] Synthesis Reference

R. J. Toivola et al., Eur. pat. Appl. 95,875; U.S. pat. 4,696,949 (1983, 1087 both to Farmos)

Toremifenum [Latin] Molecular Weight

405.959 g/mol

Toremifenum [Latin] Melting Point

108-110 oC

Toremifenum [Latin] H2O Solubility

No information avaliable

Toremifenum [Latin] State

Solid

Toremifenum [Latin] LogP

6.725

Toremifenum [Latin] Dosage Forms

Tablet

Toremifenum [Latin] Indication

For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors

Toremifenum [Latin] Pharmacology

Toremifene is an antineoplastic hormonal agent primarily used in the treatment of advanced breast cancer. Toremifene is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Toremifene inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, Toremifene appears to exert its antitumor effects by binding the estrogen receptors. In cytosols derived from human breast adenocarcinomas, Toremifene competes with estradiol for estrogen receptor protein.

Toremifenum [Latin] Absorption

Well absorbed

Toremifenum [Latin] side effects and Toxicity

No information avaliable

Toremifenum [Latin] Patient Information

Patient Information:

Vaginal bleeding has been reported in patients using Toremifene. Patients should be informed about
this and instructed to contact their physician if such bleeding occurs.

Patients with bone metastases should be informed about the typical signs and symptoms of hypercalcemia
and instructed to contact their physician for further assessment if such signs or symptoms occur.

Toremifenum [Latin] Organisms Affected

Humans and other mammals